Sofosbuvir for COVID-19 infection: A potential candidate.
作者信息
Gupta Rohit, Dhamija Puneet
机构信息
Department of Gastroenterology and Pharmacology, AIIMS, Rishikesh, Uttarakhand, India.
出版信息
Indian J Pharmacol. 2020 May-Jun;52(3):232-233. doi: 10.4103/ijp.IJP_675_20. Epub 2020 Aug 4.
Abstract
摘要
相似文献
1
Sofosbuvir for COVID-19 infection: A potential candidate.索磷布韦用于治疗新型冠状病毒肺炎感染：一个潜在的候选药物。
Indian J Pharmacol. 2020 May-Jun;52(3):232-233. doi: 10.4103/ijp.IJP_675_20. Epub 2020 Aug 4.
2
Therapeutic options for the treatment of 2019-novel coronavirus: An evidence-based approach.2019新型冠状病毒治疗的治疗选择：循证方法
Indian J Pharmacol. 2020 Jan-Feb;52(1):1-5. doi: 10.4103/ijp.IJP_119_20. Epub 2020 Mar 11.
3
Coronavirus disease 2019 infection and the cardiovascular system.2019冠状病毒病感染与心血管系统
J Cardiovasc Med (Hagerstown). 2020 Jun;21(6):403-405. doi: 10.2459/JCM.0000000000000980.
4
Is the type of diabetes treatment relevant to outcome of COVID-19?糖尿病治疗类型与新型冠状病毒肺炎的预后有关吗？
J Diabetes. 2020 Jul;12(7):486-487. doi: 10.1111/1753-0407.13047.
5
Psychiatric implications of the use of hydroxychloroquine in COVID-19 patients.新冠病毒疾病（COVID-19）患者使用羟氯喹的精神科影响
Indian J Pharmacol. 2020 May-Jun;52(3):229-231. doi: 10.4103/ijp.IJP_595_20. Epub 2020 Aug 4.
6
Statins in coronavirus outbreak: It's time for experimental and clinical studies.冠状病毒爆发中的他汀类药物：是时候进行实验和临床研究了。
Pharmacol Res. 2020 Jun;156:104803. doi: 10.1016/j.phrs.2020.104803. Epub 2020 Apr 11.
7
Sofosbuvir as a potential option for the treatment of COVID-19.索磷布韦作为治疗新冠肺炎的一种潜在选择。
Acta Biomed. 2020 May 11;91(2):236-238. doi: 10.23750/abm.v91i2.9609.
8
Deep venous thrombosis in a non-critically ill patient with novel COVID-19 infection.新型冠状病毒感染非危重症患者的深静脉血栓形成。
Thromb Res. 2020 Aug;192:27-28. doi: 10.1016/j.thromres.2020.05.015. Epub 2020 May 14.
9
Covid-19 treatment update: follow the scientific evidence.新冠病毒疾病治疗进展：遵循科学证据。
J Thromb Thrombolysis. 2020 Jul;50(1):43-53. doi: 10.1007/s11239-020-02120-9.
10
COVID-19 and relative angiotensin-converting enzyme 2 deficiency: role in disease severity and therapeutic response.新型冠状病毒肺炎与相对血管紧张素转换酶2缺乏：在疾病严重程度和治疗反应中的作用
Open Heart. 2020 Jun;7(1). doi: 10.1136/openhrt-2020-001302.
引用本文的文献
1
Clinical Characteristics, Diagnosis, and Therapeutics of COVID-19: A Review.新型冠状病毒肺炎的临床特征、诊断和治疗：综述。
Curr Med Sci. 2023 Dec;43(6):1066-1074. doi: 10.1007/s11596-023-2797-3. Epub 2023 Oct 14.
2
Severe COVID-19: Drugs and Clinical Trials.重症新型冠状病毒肺炎：药物与临床试验
J Clin Med. 2023 Apr 16;12(8):2893. doi: 10.3390/jcm12082893.
3
Comparative effectiveness of pharmacological interventions on mortality and the average length of hospital stay of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials.药物干预对 COVID-19 患者死亡率和平均住院时间的影响的比较效果：随机对照试验的系统评价和荟萃分析。
Expert Rev Anti Infect Ther. 2022 Apr;20(4):585-609. doi: 10.1080/14787210.2022.1997587. Epub 2021 Dec 29.
4
COVID-19: Characteristics and Therapeutics.新型冠状病毒肺炎（COVID-19）：特征与治疗。
Cells. 2021 Jan 21;10(2):206. doi: 10.3390/cells10020206.
本文引用的文献
1
Nucleotide Analogues as Inhibitors of SARS-CoV-2 Polymerase, a Key Drug Target for COVID-19.核苷酸类似物作为 SARS-CoV-2 聚合酶的抑制剂，是 COVID-19 的一个关键药物靶点。
J Proteome Res. 2020 Nov 6;19(11):4690-4697. doi: 10.1021/acs.jproteome.0c00392. Epub 2020 Aug 5.
2
Remdesivir for the Treatment of Covid-19 - Preliminary Report. Reply.瑞德西韦治疗新冠病毒病-初步报告。回复。
N Engl J Med. 2020 Sep 3;383(10):994. doi: 10.1056/NEJMc2022236. Epub 2020 Jul 10.
3
Sofosbuvir as Repurposed Antiviral Drug Against COVID-19: Why Were We Convinced to Evaluate the Drug in a Registered/Approved Clinical Trial?索非布韦作为抗新冠病毒再利用的抗病毒药物：为什么我们被说服在注册/批准的临床试验中评估该药物？
Arch Med Res. 2020 Aug;51(6):577-581. doi: 10.1016/j.arcmed.2020.04.018. Epub 2020 Apr 29.
4
Anti-HCV, nucleotide inhibitors, repurposing against COVID-19.抗 HCV，核苷酸抑制剂，重新用于 COVID-19。
Life Sci. 2020 May 1;248:117477. doi: 10.1016/j.lfs.2020.117477. Epub 2020 Feb 28.
5
New concepts of sofosbuvir-based treatment regimens in patients with hepatitis C.丙型肝炎患者基于索磷布韦治疗方案的新概念
Gut. 2014 Feb;63(2):207-15. doi: 10.1136/gutjnl-2013-305771. Epub 2013 Nov 19.
6
Sofosbuvir (GS-7977), a pan-genotype, direct-acting antiviral for hepatitis C virus infection.索磷布韦（GS-7977），一种用于丙型肝炎病毒感染的泛基因型、直接作用抗病毒药物。
Expert Rev Anti Infect Ther. 2013 Dec;11(12):1269-79. doi: 10.1586/14787210.2013.855126.
Zotero 插件